The U.S. Space Force has selected SpaceX and United Launch Alliance to perform the first seven launches under the National Security Space Launch Program, or NSSL, Phase 3 Lane 2 contracts, Breaking ...

The current Alzheimer’s disease therapeutic antibodies carry a sizable risk of ARIA, especially for APOE4 carriers. Researchers believe the future of amyloid immunotherapies lies in targeted brain ...

aTyr Pharma is a small-cap biotech focused on Efzofitimod for interstitial lung disease (ILD), a group of lung-scarring diseases. In 2021, the company completed a phase 1b/2a trial in pulmonary ...

HONOLULU (KHON2) — Hawaii’s largest infrastructure project is taking another big step, as the project broke ground on the next phase of the Skyline rail project. Around the clock testing starts for ...

Launching a new MMORPG against the long-established giants is a daunting prospect. World of Warcraft, FF14, Guild Wars 2, Runescape, Eve Online; the list goes on, making it a tough task to craft a ...

Ambitious MMORPG Ashes of Creation is gearing up for the next stage of its ongoing alpha test, and there's a lot to look forward to. In a new development livestream, Intrepid Studios reveals a big ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed enrollment in SHASTA-3, SHASTA-4, and MUIR-3, the company’s global Phase 3 ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Use of alternative endpoints in phase 3 oncology trials ...

Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent ESR1 mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with ...

In its first global phase 3 readout, Akeso and Summit Therapeutics’ closely watched PD-1xVEGF bispecific antibody ivonescimab reduced the risk of progression or death by 48% in patients with ...

IO Biotech's vaccines activate T cells to modify the tumor microenvironment, targeting both cancer and immune-suppressive cells. The T-win technology combines IO102 and IO103, targeting IDO and PD-L1, ...